(Rac) -BDA-366

(Rac) -BDA-366 (example 2) is the despinner of BDA-366 (HY-101083) . BDA-366 is a potent Bcl-2 antagonist (Ki=3.3 nM), binding Bcl-2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl-2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells[1][2].

Product Specifications

CAS Number

[142645-19-0]

UNSPSC

12352005

Target

Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rac-bda-366.html

Solubility

10 mM in DMSO

Smiles

O=C1C2=C(NCC3OC3)C=CC(NCC(O)CN(CC)CC)=C2C(C4=CC=CC=C41)=O

Molecular Formula

C24H29N3O4

Molecular Weight

423.50

References & Citations

[1]Spinx Pharmaceuticals Corp. Preparation of bis (hydroxyalkylamino) anthraquinones as protein kinase C inhibitors. World Intellectual Property Organization, WO9207557 A1 1992-05-14|[2]Han B, Park D, Li R, et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015;27 (6) :852-863.